Advertisement

Acta Diabetologica

, Volume 54, Issue 8, pp 769–773 | Cite as

Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study

  • Lea Querques
  • Mariacristina Parravano
  • Riccardo Sacconi
  • Alessandro Rabiolo
  • Francesco Bandello
  • Giuseppe Querques
Original Article

Abstract

Aims

To investigate the effect of dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME).

Methods

Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled. Patients underwent a comprehensive ocular examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography, ultra-widefield (UWF) retinography and UWF fluorescein angiography (UWFA).

Results

Nine eyes of seven consecutive patients (five males; mean age 66.4 ± 6.7 years) were enrolled. Mean duration of DR was 12.3 ± 8.4 years. Mean interval between UWFA acquisitions was 12.1 ± 2.1 weeks, and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Mean pre- and post-injection BCVA was 0.30 ± 0.20 and 0.21 ± 0.14 logMAR (p = 0.06), respectively. Mean pre- and post-injection central macular thickness was 449.8 ± 92.5 and 356.3 ± 52.4 μm (p = 0.03), respectively. Mean pre- and post-injection ischemic index was 24.0 ± 25.0 and 9.8 ± 12.1% (p = 0.0427), respectively.

Conclusions

Intravitreal dexamethasone implant reduces peripheral retina ischemia in patients with DR.

Keywords

Diabetic retinopathy Diabetic macular edema Ultra-widefield fluorescein angiography Ischemic index After intravitreal dexamethasone implant 

Notes

Compliance with ethical standards

Conflict of interest

Lea Querques, Alessandro Rabiolo, Maria Cristina Parravano, Riccardo Sacconi declare that they have no conflict of interest. Francesco Bandello consultant for: Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). Giuseppe Querques consultant for: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Heidelberg (Germany), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Zeiss (Dublin, USA).

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Wessel MM, Nair N, Aaker GD, Ehrlich JR, D’Amico DJ, Kiss S (2012) Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol 96(5):694–698. doi: 10.1136/bjophthalmol-2011-300774 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Witmer MT, Kiss S (2013) Wide-field imaging of the retina. Surv Ophthalmol 58(2):143–154. doi: 10.1016/j.survophthal.2012.07.003 CrossRefPubMedGoogle Scholar
  3. 3.
    Diabetic retinopathy study (1981) Report number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci 21(2):1–226Google Scholar
  4. 4.
    Soliman AZ, Silva PS, Aiello LP, Sun JK (2012) Ultra-wide field retinal imaging in detection, classification, and management of diabetic retinopathy. Semin Ophthalmol 27(5–6):221–227. doi: 10.3109/08820538.2012.708812 CrossRefPubMedGoogle Scholar
  5. 5.
    Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039 CrossRefPubMedGoogle Scholar
  6. 6.
    Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS (2014) Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 121(9):1783–1789. doi: 10.1016/j.ophtha.2014.03.021 CrossRefPubMedGoogle Scholar
  7. 7.
    Bressler NM, Edwards AR, Beck RW et al (2009) Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 127(12):1566–1571. doi: 10.1001/archophthalmol.2009.308 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Malcles A, Dot C, Voirin N et al (2016) Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. doi: 10.1097/IAE.0000000000001234 Google Scholar
  9. 9.
    Haller JA, Bandello F, Belfort R Jr et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460CrossRefPubMedGoogle Scholar
  10. 10.
    Patel RD, Messner LV, Teitelbaum B, Michel KA, Hariprasad SM (2013) Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol 155(6):1038–1044 e1032. doi: 10.1016/j.ajo.2013.01.007 CrossRefPubMedGoogle Scholar
  11. 11.
    Tan CS, Sadda SR, Hariprasad SM (2014) Ultra-widefield retinal imaging in the management of diabetic eye diseases. Ophthalmic Surg Lasers Imaging Retina 45(5):363–366. doi: 10.3928/23258160-20140909-07 CrossRefPubMedGoogle Scholar
  12. 12.
    Wessel MM, Aaker GD, Parlitsis G, Cho M, D’Amico DJ, Kiss S (2012) Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 32(4):785–791. doi: 10.1097/IAE.0b013e3182278b64 CrossRefPubMedGoogle Scholar
  13. 13.
    Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682. doi: 10.1016/S0161-6420(03)00475-5 CrossRefPubMedGoogle Scholar
  14. 14.
    Sim DA, Keane PA, Rajendram R et al (2014) Patterns of peripheral retinal and central macula ischemia in diabetic retinopathy as evaluated by ultra-widefield fluorescein angiography. Am J Ophthalmol 158(1):144–153 e141. doi: 10.1016/j.ajo.2014.03.009 CrossRefPubMedGoogle Scholar
  15. 15.
    Edelman JL, Lutz D, Castro MR (2005) Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80(2):249–258. doi: 10.1016/j.exer.2004.09.013 CrossRefPubMedGoogle Scholar
  16. 16.
    Tamura H, Miyamoto K, Kiryu J et al (2005) Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46(4):1440–1444. doi: 10.1167/iovs.04-0905 CrossRefPubMedGoogle Scholar
  17. 17.
    Dugel PU, Bandello F, Loewenstein A (2015) Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 9:1321–1335. doi: 10.2147/OPTH.S79948 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia 2017

Authors and Affiliations

  • Lea Querques
    • 1
    • 2
  • Mariacristina Parravano
    • 2
  • Riccardo Sacconi
    • 1
    • 3
  • Alessandro Rabiolo
    • 1
  • Francesco Bandello
    • 1
  • Giuseppe Querques
    • 1
  1. 1.Department of OphthalmologyUniversity Vita-Salute, IRCCS Ospedale San RaffaeleMilanItaly
  2. 2.G. B. Bietti Foundation-IRCCSRomeItaly
  3. 3.Eye Clinic, Department of Neurological and Movement SciencesUniversity of VeronaVeronaItaly

Personalised recommendations